|Bid||6.75 x 2900|
|Ask||7.20 x 1200|
|Day's Range||7.26 - 7.55|
|52 Week Range||2.10 - 7.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 5, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
Cerus Corporation announced today that the U.S. Department of the Navy will implement pathogen-reduction for all apheresis platelets collected at Navy Blood Donor Centers.
NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Torchmark ...
Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), and Cerus Corp. (NASDAQ: CERS).
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cerus Corporation (CERS), a biomedical products company focused in the field of blood transfusion safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites that may be present in donated blood.
Cerus Corporation announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCEPT-treated red blood cells in thalassemia major patients, were presented today at the 23rd Congress of European Hematology Association in Stockholm Sweden in a poster presentation entitled, “A Randomized, Controlled, Phase III Study to Evaluate S-303/Glutathione Pathogen-Inactivated ...
Cerus Corporation today announced that it will make multiple presentations, including two oral abstracts, that will be featured at the 35th International Congress of the International Society of Blood Transfusion in Toronto, Canada from June 2nd to June 6th, 2018.
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
Cerus Corporation (CERS) today announced an amendment to the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA). The expansion of the agreement provides an additional $15 million in funding for supplementary support of both the ReCePI acute anemia clinical trial and SCient chronic anemia clinical trial. “BARDA is an important partner in our mission to establish INTERCEPT as the standard of care for all transfused blood components globally,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
NEW YORK, May 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cerus ...
The Concord, California-based company said it had a loss of 11 cents per share. The biomedical products company posted revenue of $13.6 million in the period. Cerus expects full-year revenue in the range ...
Cerus Corporation announced today financial results for the first quarter ended March 31, 2018, and raised its full year guidance for product revenue.
Cerus Corporation (CERS) announced today that Dr. Laurence M. Corash, co-founder and chief scientific officer, and Lainie Corten, vice president of global marketing, are scheduled to present a corporate update at the Deutsche Bank 43rd Annual Health Care Conference at the InterContinental Hotel Boston on Wednesday, May 9th at 1:30 pm ET. Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood.
Cerus Corporation announced today that its first quarter results will be released on Tuesday, May 8, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
Cerus Corporation announced today that Health Canada has approved the commercialization of INTERCEPT Blood System for platelets. The INTERCEPT Blood System for platelets is intended for the ex vivo treatment and storage of platelet components.
Cerus Corporation announced today that Baylor St. Luke’s Medical Center in Houston became the first center in the continental U.S. to enroll patients in Cerus’ RedeS study.
Longtime Concord company Cerus Corp. signed a lease with Sierra Pacific Properties for a new headquarters office.
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
Stock Monitor: Cerus Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 16, 2018 / Active-Investors.com has just released a free research report on Tyme Technologies, Inc. (NASDAQ: TYME ). If you ...
Investors are always looking for growth in small-cap stocks like Cerus Corporation (NASDAQ:CERS), with a market cap of US$664.83M. However, an important fact which most ignore is: how financially healthyRead More...
Cerus Corporation announced today that The Community Blood Center of Appleton, Wisconsin received approval by the U.S. Food and Drug Administration on their Biologics License Application requesting allowance of interstate distribution of platelets that have been pathogen-reduced with the INTERCEPT Blood System.
The Concord, California-based company said it had a loss of 10 cents per share. The biomedical products company posted revenue of $16.2 million in the period. For the year, the company reported that its ...